Evaluation of Residual Symptoms and Anxiety Among Patients on Therapy for Benign Prostatic Hyperplasia at a Nigerian Tertiary Healthcare Facility

The study conducted at Ibrahim Badamasi Specialist Hospital Minna involved 412 outpatients and assessed the prevalence of residual symptoms and clinical anxiety in patients undergoing pharmacotherapy for benign prostatic hyperplasia (BPH). Using the Memorial anxiety scale for prostate cancer (MAX-PC) and the expanded prostate cancer index composite for clinical practice (EPIC-CP), it was found that 44.3% of patients experienced high anxiety, primarily due to fears of recurrence (91.3%), BPH progression (23.3%), and prostate-specific antigen tests (9.3%). Common residual symptoms included sexual dysfunction (96.1%), urinary incontinence (37.6%), and urinary obstruction (34.5%). There was a significant association between residual symptoms and demographic factors (p<0.001). The findings highlight the need for routine anxiety assessment and treatment to improve patients' quality of life.